| Vol. 9.37 – 24 September, 2020 |
| |
|
|
| Researchers report that one of the interferon‐stimulated genes, cholesterol 25‐hydroxylase, was induced by SARS‐CoV‐2 infection in vitro and in COVID‐19 patients. [EMBO Journal] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists exposed the human alveolar A549 cell line to 0, 200, and 500 μg/mL quartz particles for 24 hours and used gas chromatography–mass spectrometry to measure the volatile metabolites in the headspace air of cells. [Scientific Reports] |
|
|
|
| Researchers characterized the contribution of one of the identified genes, MBIP, towards driving tumor invasion and metastasis. They demonstrated that expression of MBIP significantly enhanced the cellular proliferation, migration and invasion of NSCLC cells in vitro and metastasis in vivo. [Oncogene] |
|
|
|
| CB11 caused cell death via reactive oxygen species-mediated ATM-p53-GADD45α signaling in human non-small-cell lung cancer cells, and diphenyleneiodonium, an NADPH oxidase inhibitor, decreased cell death by inhibiting CB11-mediated ATM signaling. [British Journal of Cancer] |
|
|
|
| The authors identified a long noncoding RNA LINC00857 that might regulate radio-sensitivity of lung adenocarcinoma cells. [Molecular Therapy-Nucleic Acids] |
|
|
|
| Investigators found that miR-196b-5p promoted lung cancer cell proliferation and colony formation by directly targeting tumor suppressor, FAS. [Cell Death & Disease] |
|
|
|
| Scientists analyzed the anticancer potential of hmxbato against lung tumor cells, as well as the partial death mechanisms involved. [Scientific Reports] |
|
|
|
| The authors investigated the anti-tumor functions and the feasible molecular basis of nitidine chloride in NSCLC cells. [Cell Death Discovery] |
|
|
|
| In vitro assays on immortalized and patient-derived primary non-small cell lung cancer cells revealed that miR-34c-3p overexpression increased apoptosis and lowered proliferation rate in KRASmut cells. [Cancer Gene Therapy] |
| |
|
|
| A tumor xenograft mouse model was used to determine role of extracellular vesicles-microRNA-130b-3p and its target FOXO3 in lung cancer progression in vivo. [Molecular Therapy-Oncolytics] |
|
|
|
|
| Non‐small cell lung cancer (NSCLC) is the leading cause of cancer death and in most cases it is often diagnosed at an advanced stage. Many genetic and microenvironmental factors are able to modify the cell cycle inducing carcinogenesis and tumor growth. [Thoracic Cancer] |
|
|
|
|
| The Janssen Pharmaceutical Companies of Johnson & Johnson announced interim results from the CHRYSALIS study, evaluating amivantamab, a fully human bispecific antibody that targets epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor mutations, in combination with the third-generation EGFR tyrosine kinase inhibitor lazertinib in patients with non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations. [Janssen Global Services, LLC] |
|
|
|
| Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of Opdivo® plus Yervoy® with two cycles of platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumors have no sensitizing EGFR mutation or ALK translocation. [Bristol Myers Squibb] |
|
|
|
|
| December 1 – December 2 Virtual |
|
|
|
|
|
| Old Dominion University – Norfolk, Virginia, United States |
|
|
|
| Justus-Liebig-Universität Gießen – Gießen, Germany |
|
|
|
| NYU Langone Health – New York, New York, United States |
|
|
|
| Institut Mondor de Recherche Biomédicale (IMRB) – Creteil, France |
|
|
|
| National Heart and Lung Institute – London, United Kingdom |
|
|
|
|